Potential drug interactions in cancer therapy: a prevalence study using an advanced screening method
Open Access
- 22 February 2011
- journal article
- research article
- Published by Elsevier BV in Annals Of Oncology
- Vol. 22 (10), 2334-2341
- https://doi.org/10.1093/annonc/mdq761
Abstract
Background: In cancer patients, drug interactions may intensify adverse events or reduce antitumour effects. We assessed the prevalence of potential drug interactions (PDIs) among ambulatory cancer patients on i.v. treatment using an advanced screening method. Patients and methods: Data on drugs used for comorbidities, anticancer agents, over-the-counter (OTC) drugs, and comorbidities were collected by means of a structured interview among the patients and review of medical charts. PDIs were identified using electronic (Drug Interaction Facts software, version 4.0) and manual screening methods (peer-reviewed reports). Results: In this study, 278 patients were enrolled. We identified 348 PDIs. Of all patients, 161 (58%) had at least one PDI. Of all PDIs, 34% was classified as major and 60% as moderate. Coumarins, quinolones, antiepileptics, and hydrochlorothiazide were frequently part of a PDI. Interactions that potentially cause QT interval prolongation, gastrointestinal toxicity, and central nervous system depression were also common. In multivariate analysis, an increasing number of drugs [odds ratio (OR) = 1.4, confidence interval (CI) 1.23–1.52; P < 0.001] and the use of an OTC drug (OR = 0.56, CI 0.32–0.97; P = 0.045) were risk factors. Conclusions: PDIs are common in patients treated for an (haemato-) oncological disease. Screening for potential interactions should take place routinely before administering chemotherapy.Keywords
This publication has 42 references indexed in Scilit:
- Potential Drug Interactions and Duplicate Prescriptions Among Cancer PatientsJNCI Journal of the National Cancer Institute, 2007
- Drug interactions in cancer therapyNature Reviews Cancer, 2006
- Drug-drug interactions among recently hospitalised patients – frequent but mostly clinically insignificantEuropean Journal of Clinical Pharmacology, 2005
- Potential for drug interactions in hospitalized cancer patientsCancer Chemotherapy and Pharmacology, 2005
- Drug interactions in oncologyThe Lancet Oncology, 2004
- Potential drug–drug interactions in the medication of medical patients at hospital dischargeEuropean Journal of Clinical Pharmacology, 2003
- Arzneimittelwechselwirkungen im klinischen AlltagDie Dermatologie, 2002
- Fatal adverse drug events: the paradox of drug treatmentJournal of Internal Medicine, 2001
- Drug-drug interactions in medical patients: Effects of in-hospital treatment and relation to multiple drug useInternational journal of clinical pharmacology and therapeutics, 2000
- Drug-drug and drug-disease interactions in the ED: Analysis of a high-risk populationThe American Journal of Emergency Medicine, 1996